Advanced Glycation End Products (AGEs): Emerging Mediators of Skin Aging

Living reference work entry
First Online:
Received:
Accepted:

Abstract

Advanced glycation end products (AGEs) derive from nonenzymatic reactions between reducing sugars and proteins, lipids or nucleic acids. In this chapter, we highlight the role of AGEs as an emerging class of mediators of skin aging. After a short section on the biochemistry and biology of AGEs we will put these molecules into the context of skin aging. Evidence will be provided that: (1) AGEs are detectable in skin, (2) that they accumulate over time in aged skin, and (3) that they act via diverse mechanisms (receptor and nonreceptor-mediated) on various cellular and noncellular targets of the skin. Special emphasis will be devoted to the connections between AGEs and reactive oxygen species, the latter established players of cutaneous aging. Finally, current and future strategies are described by which the impact of AGEs on skin aging may be counteracted.

Keywords

Advanced glycation end products AGEs Skin aging Photoaging Fibroblasts Keratinocytes UV Oxidative stress ROS 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005;67:3–21.PubMedCrossRefGoogle Scholar
  2. 2.
    Maillard LC. Action des acides amines sur les sucres: formation des melanoidines par voie methodique. C R Acad Sci (Paris). 1912;154:66–8.Google Scholar
  3. 3.
    Hodge JE. Dehydrated foods, chemistry of browning reactions in model systems. J Agric Food Chem. 1953;1:928–43.CrossRefGoogle Scholar
  4. 4.
    Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A. 2002;99:15596–601.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    DeGroot J, Verzijl N, Wenting-Van Wijk MJ, Bank RA, Lafeber FP, Bijlsma JW, et al. Age-related decrease in susceptibility of human articular cartilage to matrix metalloproteinase-mediated degradation: the role of advanced glycation end products. Arthritis Rheum. 2001;44:2562–71.PubMedCrossRefGoogle Scholar
  6. 6.
    Kawabata K, Yoshikawa H, Saruwatari K, Akazawa Y, Inoue T, Kuze T, et al. The presence of N(ε)-(carboxymethyl) lysine in the human epidermis. Biochim Biophys Acta. 2011;1814:1246–52.PubMedCrossRefGoogle Scholar
  7. 7.
    Jeanmaire C, Danoux L, Pauly G. Glycation during human dermal intrinsic and actinic ageing: an in vivo and in vitro model study. Br J Dermatol. 2001;145:10–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest. 1993;91:2463–9.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Mizutari K, Ono T, Ikeda K, Kayashima K, Horiuchi S. Photo-enhanced modification of human skin elastin in actinic elastosis by N(epsilon)-(carboxymethyl)lysine, one of the glycoxidation products of the Maillard reaction. J Invest Dermatol. 1997;108:797–802.PubMedCrossRefGoogle Scholar
  10. 10.
    Kueper T, Grune T, Prahl S, Lenz H, Welge V, Biernoth T, et al. Vimentin is the specific target in skin glycation. Structural prerequisites, functional consequences, and role in skin aging. J Biol Chem. 2007;282:23427–36.PubMedCrossRefGoogle Scholar
  11. 11.
    Fan X, Sell DR, Zhang J, Nemet I, Theves M, Lu J, et al. Anaerobic vs aerobic pathways of carbonyl and oxidant stress in human lens and skin during aging and in diabetes: a comparative analysis. Free Radic Biol Med. 2010;49:847–56.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Frye EB, Degenhardt TP, Thorpe SR, Baynes JW. Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins. J Biol Chem. 1998;273:18714–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. N epsilon-(carboxymethyl) lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry. 1995;34:10872–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Sell DR, Monnier VM. Isolation, purification and partial characterization of novel fluorophores from aging human insoluble collagen-rich tissue. Connect Tissue Res. 1989;19:77–92.PubMedCrossRefGoogle Scholar
  15. 15.
    Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J. 1999;344:109–16.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A. 1997;94:13915–20.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G, et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci. 2007;62:427–33.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004;104:1287–91.PubMedCrossRefGoogle Scholar
  19. 19.
    Leslie RD, Beyan H, Sawtell P, Boehm BO, Spector TD, Snieder H. Level of an advanced glycated end product is genetically determined: a study of normal twins. Diabetes. 2003;52:2441–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Xue M, Rabbani N, Thornalley PJ. Glyoxalase in ageing. Semin Cell Dev Biol. 2011;22:293–301.PubMedCrossRefGoogle Scholar
  21. 21.
    Van Schaftingen E, Collard F, Wiame E, Veiga-da-Cunha M. Enzymatic repair of Amadori products. Amino Acids. 2012;42:1143–50.PubMedCrossRefGoogle Scholar
  22. 22.
    Grimm S, Horlacher M, Catalgol B, et al. Cathepsins D and L reduce the toxicity of advanced glycation end products. Free Radic Biol Med. 2012;52:1011–23. doi:10.1016/j.freeradbiomed.2011.12.021.PubMedCrossRefGoogle Scholar
  23. 23.
    Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl). 2005;83:876–86.CrossRefGoogle Scholar
  24. 24.
    Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology. 2005;15:16R–28.PubMedCrossRefGoogle Scholar
  25. 25.
    Vazzana N, Santilli F, Cuccurullo C, et al. Soluble forms of RAGE in internal medicine. Intern Emerg Med. 2009;4:389–401. doi:10.1007/s11739-009-0300-1.PubMedCrossRefGoogle Scholar
  26. 26.
    Lu C, He JC, Cai W, Liu H, Zhu L, Vlassara H. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci U S A. 2004;101:11767–72.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Lohwasser C, Neureiter D, Weigle B, Kirchner T, Schuppanm D. The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. J Invest Dermatol. 2006;126:291–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Meerwaldt R, Links T, Graaff R, Thorpe SR, Baynes JW, Hartog J, et al. Simple noninvasive measurement of skin autofluorescence. Ann N Y Acad Sci. 2005;1043:290–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Corstjens HM, Dicanio D, Muizzuddin N, Neven A, Sparacio R, Declercq L, et al. Glycation associated skin autofluorescence and skin elasticity are related to chronological age and body mass index of healthy subjects. Exp Gerontol. 2008;43:663–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Dunn JA, McCance DR, Thorpe SR, Lyons TJ, Baynes JW. Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry. 1991;30:1205–10.PubMedCrossRefGoogle Scholar
  31. 31.
    Pageon H. Reaction of glycation and human skin: the effects on the skin and its components, reconstructed skin as a model. Pathol Biol (Paris). 2010;58:226–31.CrossRefGoogle Scholar
  32. 32.
    Smit AJ, Gerrits EG. Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease. Curr Opin Nephrol Hypertens. 2010;19:527–33.PubMedCrossRefGoogle Scholar
  33. 33.
    Avery NC, Bailey AJ. The effects of the Maillard reaction on the physical properties and cell interactions of collagen. Pathol Biol (Paris). 2006;54:387–95.CrossRefGoogle Scholar
  34. 34.
    Haitoglou CS, Tsilibary EC, Brownlee M, Charonis AS. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem. 1992;267:12404–7.PubMedGoogle Scholar
  35. 35.
    Haucke E, Navarrete-Santos A, Simm A, et al. Glycation of extracellular matrix proteins impairs migration of immune cells. Wound Repair Regen. 2014;22:239–45. doi:10.1111/wrr.12144.PubMedCrossRefGoogle Scholar
  36. 36.
    Yoshinaga E, Kawada A, Ono K, Fujimoto E, Wachi H, Harumiya S, et al. N(ɛ)-(carboxymethyl)lysine modification of elastin alters its biological properties: implications for the accumulation of abnormal elastic fibers in actinic elastosis. J Invest Dermatol. 2012;132:315–23.PubMedCrossRefGoogle Scholar
  37. 37.
    Jacobsen JN, Steffensen B, Häkkinen L, et al. Skin wound healing in diabetic β6 integrin-deficient mice. APMIS. 2010;118:753–64. doi:10.1111/j.1600-0463.2010.02654.x.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Reihsner R, Melling M, Pfeiler W, Menzel EJ. Alterations of biochemical and two-dimensional biomechanical properties of human skin in diabetes mellitus as compared to effects of in vitro non-enzymatic glycation. Clin Biomech. 2000;15:379–86.CrossRefGoogle Scholar
  39. 39.
    Yoon HS, Baik SH, Oh CH. Quantitative measurement of desquamation and skin elasticity in diabetic patients. Skin Res Technol. 2002;8:250–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Uchiki T, Weikel KA, Jiao W, Shang F, Caceres A, Pawlak D, et al. Glycation-altered proteolysis as a pathobiologic mechanism that links dietary glycemic index, aging, and age-related disease (in non diabetics). Aging Cell. 2012;11:1–13.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Ukeda H, Hasegawa Y, Ishi T, Sawamiura M. Inactivation of Cu, Zn-superoxide dismutase by intermediates of Maillard reaction and glycolytic pathway and some sugars. Biosci Biotechnol Biochem. 1997;61:2039–42.PubMedCrossRefGoogle Scholar
  42. 42.
    Baynes JW. The Maillard hypothesis on aging: time to focus on DNA. Ann N Y Acad Sci. 2002;959:360–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest. 1994;94:110–7.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Portero-Otín M, Pamplona R, Bellmunt MJ, Ruiz MC, Prat J, Salvayre R, et al. Advanced glycation end product precursors impair epidermal growth factor receptor signaling. Diabetes. 2002;51:1535–42.PubMedCrossRefGoogle Scholar
  45. 45.
    Zhu P, Yang C, Chen LH, Ren M, Lao GJ, Yan L. Impairment of human keratinocyte mobility and proliferation by advanced glycation end products-modified BSA. Arch Dermatol Res. 2011;303:339–50.PubMedCrossRefGoogle Scholar
  46. 46.
    Berge U, Behrens J, Rattan SI. Sugar-induced premature aging and altered differentiation in human epidermal keratinocytes. Ann N Y Acad Sci. 2007;1100:524–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Wondrak GT, Roberts MJ, Jacobson MK, Jacobson EL. Photosensitized growth inhibition of cultured human skin cells: mechanism and suppression of oxidative stress from solar irradiation of glycated proteins. J Invest Dermatol. 2002;119:489–98.PubMedCrossRefGoogle Scholar
  48. 48.
    Zhu P, Ren M, Yang C, Hu YX, Ran JM, Yan L. Involvement of RAGE, MAPK and NF-κB pathways in AGEs-induced MMP-9 activation in HaCaT keratinocytes. Exp Dermatol. 2012;21:123–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Alikhani Z, Alikhani M, Boyd CM, Nagao K, Trackman PC, Graves DT. Advanced glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways. J Biol Chem. 2005;280:12087–95.PubMedCrossRefGoogle Scholar
  50. 50.
    Molinari J, Ruszova E, Velebny V, Robert L. Effect of advanced glycation endproducts on gene expression profiles of human dermal fibroblasts. Biogerontology. 2008;9:177–82.PubMedCrossRefGoogle Scholar
  51. 51.
    Sejersen H, Rattan SI. Dicarbonyl-induced accelerated aging in vitro in human skin fibroblasts. Biogerontology. 2009;10:203–11.PubMedCrossRefGoogle Scholar
  52. 52.
    Schmidt AM, Hori O, Chen J, Li JF, Crandall J, Zhang J, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1): a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest. 1995;96:1395–403.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Lan CC, Wu CS, Huang SM, et al. High-glucose environment reduces human β-defensin-2 expression in human keratinocytes: implications for poor diabetic wound healing. Br J Dermatol. 2012;166:1221–9. doi:10.1111/j.1365-2133.2012.10847.x.PubMedCrossRefGoogle Scholar
  54. 54.
    Iotzova-Weiss G, Dziunycz PJ, Freiberger SN, et al. S100A8/A9 stimulates keratinocyte proliferation in the development of squamous cell carcinoma of the skin via the receptor for advanced glycation-end products. PLoS One. 2015;10, e0120971. doi:10.1371/journal.pone.0120971.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Masaki H, Okano Y, Sakurai H. Generation of active oxygen species from advanced glycation end-products (AGE) under ultraviolet light A (UVA) irradiation. Biochem Biophys Res Commun. 1997;235:306–10.PubMedCrossRefGoogle Scholar
  56. 56.
    San Martin A, Foncea R, Laurindo FR, Ebensperger R, Griendling KK, Leighton F. Nox1-based NADPH oxidase-derived superoxide is required for VSMC activation by advanced glycation end-products. Free Radic Biol Med. 2007;42(11):1671–9. Epub 2007 Feb 12.PubMedCrossRefGoogle Scholar
  57. 57.
    Zhang M, Kho AL, Anilkumar N, Chibber R, Pagano PJ, Shah AM, Cave AC. Glycated proteins stimulate reactive oxygen species production in cardiac myocytes: involvement of Nox2 (gp91phox)-containing NADPH oxidase. Circulation. 2006;113(9):1235–43. Epub 2006 Feb 27.PubMedCrossRefGoogle Scholar
  58. 58.
    Loughlin DT, Artlett CM. Precursor of advanced glycation end products mediates ER-stress-induced caspase-3 activation of human dermal fibroblasts through NAD(P)H oxidase 4. PLoS One. 2010;5(6), e11093. doi:10.1371/journal.pone.0011093.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Omori K, Ohira T, Uchida Y, Ayilavarapu S, Batista Jr EL, Yagi M, et al. Priming of neutrophil oxidative burst in diabetes requires preassembly of the NADPH oxidase. J Leukoc Biol. 2008;84(1):292–301. doi:10.1189/jlb.1207832. Epub 2008 Apr 7.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Yim MB, Yim HS, Lee C, Kang SO, Chock PB. Protein glycation: creation of catalytic sites for free radical generation. Ann N Y Acad Sci. 2001;928:48–53.PubMedCrossRefGoogle Scholar
  61. 61.
    Elosta A, Ghous T, Ahmed N. Natural products as anti-glycation agents: possible therapeutic potential for diabetic complications. Curr Diabetes Rev. 2012;8:92–108.PubMedCrossRefGoogle Scholar
  62. 62.
    Reddy VP, Beyaz A. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discov Today. 2006;11:646–54.PubMedCrossRefGoogle Scholar
  63. 63.
    Cadau S, Leoty-Okombi S, Pain S, et al. In vitro glycation of an endothelialized and innervated tissue-engineered skin to screen anti-AGE molecules. Biomaterials. 2015;51:216–25. doi:10.1016/j.biomaterials.2015.01.066.PubMedCrossRefGoogle Scholar
  64. 64.
    Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 2002;61:939–50.PubMedCrossRefGoogle Scholar
  65. 65.
    Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys. 2003;419:89–96.PubMedCrossRefGoogle Scholar
  66. 66.
    Xue M, Rabbani N, Momiji H, Imbasi P, Anwar MM, Kitteringham N, et al. Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochem J. 2012;443:213–22.PubMedCrossRefGoogle Scholar
  67. 67.
    Dearlove RP, Greenspan P, Hartle DK, Swanson RB, Hargrove JL. Inhibition of protein glycation by extracts of culinary herbs and spices. J Med Food. 2008;11:275–81.PubMedCrossRefGoogle Scholar
  68. 68.
    Wu CH, Yen GC. Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation endproducts. J Agric Food Chem. 2005;53:3167–73.PubMedCrossRefGoogle Scholar
  69. 69.
    Draelos ZD, Yatskayer M, Raab S, Oresajo C. An evaluation of the effect of a topical product containing C-xyloside and blueberry extract on the appearance of type II diabetic skin. J Cosmet Dermatol. 2009;8:147–51.PubMedCrossRefGoogle Scholar
  70. 70.
    Ohno R, Moroishi N, Sugawa H, et al. Mangosteen pericarp extract inhibits the formation of pentosidine and ameliorates skin elasticity. J Clin Biochem Nutr. 2015;57:27–32. doi:10.3164/jcbn.15-13.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Yamagishi S, Ueda S, Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des. 2007;13:2832–6.PubMedCrossRefGoogle Scholar
  72. 72.
    Peppa M, Brem H, Ehrlich P, Zhang JG, Cai W, Li Z, et al. Adverse effects of glycotoxins on wound healing in genetically diabetic mice. Diabetes. 2003;52:2805–13.PubMedCrossRefGoogle Scholar
  73. 73.
    Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes. 1999;48:870–80.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Hudson BI, Bucciarelli LG, Wendt T, Sakaguchi T, Lalla E, Qu W, et al. Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys. 2003;419:80–8.PubMedCrossRefGoogle Scholar
  75. 75.
    Goova MT, Li J, Kislinger T, Qu W, Lu Y, Bucciarelli LG, et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol. 2001;159:513–25.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Babizhayev MA, Nikolayev GM, Nikolayeva JG, Yegorov YE. Biologic activities of molecular chaperones and pharmacologic chaperone imidazole-containing dipeptide-based compounds: natural skin care help and the ultimate challenge. Implication for adaptive responses in the skin. Am J Ther. 2012;19:69–89.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Dermatology, Laboratory for Neuroendocrinology of the Skin and Interdisciplinary EndocrinologyUniversity of MünsterMünsterGermany

Personalised recommendations